These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 17014391)

  • 21. Strategies for dealing with reactive intermediates in drug discovery and development.
    Nassar AE; Lopez-Anaya A
    Curr Opin Drug Discov Devel; 2004 Jan; 7(1):126-36. PubMed ID: 14982156
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Toxicogenomics in drug discovery: from preclinical studies to clinical trials.
    Yang Y; Blomme EA; Waring JF
    Chem Biol Interact; 2004 Nov; 150(1):71-85. PubMed ID: 15522262
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular imaging strategies for drug discovery and development.
    Gross S; Piwnica-Worms D
    Curr Opin Chem Biol; 2006 Aug; 10(4):334-42. PubMed ID: 16822702
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development.
    Whitebread S; Hamon J; Bojanic D; Urban L
    Drug Discov Today; 2005 Nov; 10(21):1421-33. PubMed ID: 16243262
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Compound optimization in early- and late-phase drug discovery: acceptable pharmacokinetic properties utilizing combined physicochemical, in vitro and in vivo screens.
    Caldwell GW
    Curr Opin Drug Discov Devel; 2000 Jan; 3(1):30-41. PubMed ID: 19649835
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical pharmacology of anticancer agents in relation to formulations and administration routes.
    Terwogt JM; Schellens JH; Huinink WW; Beijnen JH
    Cancer Treat Rev; 1999 Apr; 25(2):83-101. PubMed ID: 10395834
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent advances in pharmacokinetic modeling.
    Ahmad AM
    Biopharm Drug Dispos; 2007 Apr; 28(3):135-43. PubMed ID: 17295411
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vivo toxicology of excipients commonly employed in drug discovery in rats.
    Gopinathan S; O'Neill E; Rodriguez LA; Champ R; Phillips M; Nouraldeen A; Wendt M; Wilson AGE; Kramer JA
    J Pharmacol Toxicol Methods; 2013; 68(2):284-295. PubMed ID: 23499653
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Caenorhabditis elegans: a versatile platform for drug discovery.
    Artal-Sanz M; de Jong L; Tavernarakis N
    Biotechnol J; 2006 Dec; 1(12):1405-18. PubMed ID: 17109493
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Applications of physiologically based absorption models in drug discovery and development.
    Parrott N; Lave T
    Mol Pharm; 2008; 5(5):760-75. PubMed ID: 18547054
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of pharmacodynamic research in the assessment and development of new antibacterial drugs.
    Lister PD
    Biochem Pharmacol; 2006 Mar; 71(7):1057-65. PubMed ID: 16316633
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biopharmaceutical challenges associated with drugs with low aqueous solubility--the potential impact of lipid-based formulations.
    O'Driscoll CM; Griffin BT
    Adv Drug Deliv Rev; 2008 Mar; 60(6):617-24. PubMed ID: 18155800
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Obtaining exposures of metabolites in preclinical species through plasma pooling and quantitative NMR: addressing metabolites in safety testing (MIST) guidance without using radiolabeled compounds and chemically synthesized metabolite standards.
    Vishwanathan K; Babalola K; Wang J; Espina R; Yu L; Adedoyin A; Talaat R; Mutlib A; Scatina J
    Chem Res Toxicol; 2009 Feb; 22(2):311-22. PubMed ID: 19067650
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Systematic approaches to toxicology in the zebrafish.
    Peterson RT; Macrae CA
    Annu Rev Pharmacol Toxicol; 2012; 52():433-53. PubMed ID: 22017682
    [TBL] [Abstract][Full Text] [Related]  

  • 35. When poor solubility becomes an issue: from early stage to proof of concept.
    Stegemann S; Leveiller F; Franchi D; de Jong H; Lindén H
    Eur J Pharm Sci; 2007 Aug; 31(5):249-61. PubMed ID: 17616376
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Embracing complexity in drug discovery.
    Gund P; Maliski E; Brown F
    Curr Opin Drug Discov Devel; 2007 May; 10(3):252-3. PubMed ID: 17554850
    [No Abstract]   [Full Text] [Related]  

  • 37. A holistic strategy for characterizing the safety of metabolites through drug discovery and development.
    Walker D; Brady J; Dalvie D; Davis J; Dowty M; Duncan JN; Nedderman A; Obach RS; Wright P
    Chem Res Toxicol; 2009 Oct; 22(10):1653-62. PubMed ID: 19715349
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vivo drug discovery in the zebrafish.
    Zon LI; Peterson RT
    Nat Rev Drug Discov; 2005 Jan; 4(1):35-44. PubMed ID: 15688071
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development and application of physiologically based pharmacokinetic-modeling tools to support drug discovery.
    Lüpfert C; Reichel A
    Chem Biodivers; 2005 Nov; 2(11):1462-86. PubMed ID: 17191947
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Application of genomics in preclinical drug safety evaluation.
    Lord PG; Nie A; McMillian M
    Basic Clin Pharmacol Toxicol; 2006 Jun; 98(6):537-46. PubMed ID: 16700814
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.